サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1739291

ウロキナーゼの世界市場

Urokinase

出版日
ページ情報
英文 279 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.36円
ウロキナーゼの世界市場
出版日: 2025年06月03日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 279 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ウロキナーゼの世界市場は2030年までに24億米ドルに達する

2024年に18億米ドルと推定されるウロキナーゼの世界市場は、2024年から2030年にかけてCAGR 4.6%で成長し、2030年には24億米ドルに達すると予測されます。ウロキナーゼ粉末は、本レポートで分析したセグメントの1つであり、CAGR 5.3％を記録し、分析期間終了時には17億米ドルに達すると予測されています。ウロキナーゼ溶液セグメントの成長率は、分析期間中CAGR 3.0％と推定されます。

米国市場は5億290万米ドル、中国はCAGR8.5％で成長予測

米国のウロキナーゼ市場は、2024年に5億290万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR 8.5%を牽引し、2030年には予測市場規模5億600万米ドルに達すると予測されます。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.9%と3.6%と予測されています。欧州では、ドイツがCAGR 2.7%で成長すると予測されています。

世界のウロキナーゼ市場- 主要動向と促進要因のまとめ

ウロキナーゼが血栓溶解療法において臨床的に再注目されている理由とは？

ウロキナーゼは、世界の血栓溶解療法、特に肺塞栓症、深部静脈血栓症（DVT）、カテーテル閉塞の治療において、重要な薬剤として再浮上しています。心血管疾患と血栓性障害が世界の罹患率と死亡率の統計の上位を占め続ける中、効率的な血栓溶解剤の必要性は最も高いです。ウロキナーゼは、元来ヒト腎臓細胞由来のセリンプロテアーゼ酵素であり、プラスミノーゲンをプラスミンに変換することにより機能し、フィブリン凝血塊を分解します。ウロキナーゼは、合成酵素とは異なり、免疫原性が低く、プラスミノーゲンを直接活性化するため、迅速な血栓溶解が必要な症例に非常に有効です。また、その応用は血管内での使用にとどまらず、膿胸や限局性胸水に対する胸膜内線溶療法のような適応外の領域にも広がっています。血液透析や中心静脈アクセスにおけるカテーテル開存性の回復における有効性を支持する臨床エビデンスの増加により、ウロキナーゼはアルテプラーゼやストレプトキナーゼに代わるものを求める医療従事者の間で支持を集めています。新しい生物学的製剤のコストや入手可能性に対する懸念が高まる中、ウロキナーゼの比較的安定した生産パイプラインは、クリティカルケアの現場において頼りになる血栓溶解薬として位置づけられています。

技術の進歩は、ウロキナーゼの製造と安定性をどのように向上させているか？

現代のバイオテクノロジーの革新は、ウロキナーゼの製造、精製、安定性を著しく向上させています。従来はヒト尿または腎細胞培養物から供給されていましたが、最近のシフトは収量、純度、スケーラビリティを向上させるための組換えDNA技術と細胞培養の最適化に焦点を当てています。製造業者は、より高い一貫性と生物学的汚染物質を低減したウロキナーゼを製造するために、チャイニーズハムスター卵巣（CHO）細胞株やその他の発現系を採用することが多くなってきています。凍結乾燥（凍結乾燥）製剤は、ウロキナーゼの保存可能期間と保存要件を改善し、救急医療や地方医療での幅広い使用を可能にしました。さらに、酵素安定化技術の進歩により、寒冷連鎖に依存することなく輸送や投与が容易な耐熱性製剤が開発されています。高速液体クロマトグラフィー（HPLC）や質量分析計などの分析技術は、現在では力価やバッチの均一性を保証するために日常的に採用されており、これは規制の厳しい医薬品市場において極めて重要です。このような機能強化は、製造コストの削減だけでなく、法規制の遵守を容易にし、先進国と新興国の両方のヘルスケアシステムで広く利用される道を開いています。

ウロキナーゼの用途を広げる臨床と市場の動向とは？

ウロキナーゼのアプリケーションベースは、臨床プロトコルの変化と世界ヘルスケアへのアクセスの拡大によって拡大しています。病院や外来センターでは、化学療法、非経口栄養、透析などで使用される閉塞したカテーテルの機能回復にウロキナーゼを使用するケースが増えています。クリティカルケアでは、ウロキナーゼは、より強力な薬剤の全身投与が過剰な出血リスクをもたらす可能性のある選択的血栓溶解プロトコールに使用されています。また、比較的良好な安全性プロファイルを有することから、小児の血栓溶解療法でも使用されるようになってきています。多くの中低所得国では、ウロキナーゼは手頃な価格とシンプルな製造ロジスティックスにより、血栓溶解剤の入手可能性とコストにおける地理的格差もウロキナーゼの市場軌跡を形成しています。アジアとラテンアメリカの規制機関は特に協力的で、承認経路を早め、ウロキナーゼを国の治療ガイドラインに組み込んでいます。さらに、抗生物質耐性が高まり、留置カテーテルによる合併症が増加する中、ウロキナーゼの感染予防と早期血栓溶解の役割は、臨床医の間で注目を集めています。

世界のウロキナーゼ市場拡大の主な要因は？

ウロキナーゼ市場の成長は、臨床需要、バイオ製造の開拓、治療プロトコルの進化に支えられたいくつかの要因によってもたらされます。特に、高齢化社会とがんや慢性腎臓病などの合併症を持つ患者における血栓塞栓イベントの発生率の上昇が大きな原動力となっています。このため、脆弱な患者群における安全性が証明された信頼性の高い血栓溶解薬に対する需要が高まっています。遺伝子組換え生産技術の進歩により、よりコスト効率が高く、スケーラブルな製造が可能になり、高所得層と資源に乏しい環境の両方におけるアクセスが拡大しています。中心静脈カテーテルや透析ラインの使用が増加していることも、カテーテル開存剤としてのウロキナーゼの需要を押し上げています。これと並行して、医療機関のコスト抑制戦略や支払者の圧力により、ヘルスケアプロバイダーは高価な新型生物製剤の代替品を求めており、ウロキナーゼは処方計画における有力な選択肢となっています。アジア太平洋および中南米市場における規制当局の支援は、特定の使用事例に関する臨床ガイドラインへの新たな記載と相まって、市場浸透をさらに促進しています。最後に、血栓溶解療法の外来・通院への分散化により、従来の病院環境以外にもウロキナーゼの新たな採用ルートが開かれつつあります。

セグメント

タイプ（ウロキナーゼパウダー,ウロキナーゼソリューション）;エンドユース（病院,クリニック）

調査対象企業の例（全48件）

  • Abbott Laboratories
  • Agrata Biotech Ltd.
  • BBT Biotech GmbH
  • Bharat Serums and Vaccines Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Cerbios-Pharma SA
  • Echelon Biosciences Inc.
  • Hanways Chempharm Co., Ltd.
  • Health Biotech Ltd.
  • ImaRx Therapeutics, Inc.
  • Jiangsu Aidea Pharmaceutical Co., Ltd.
  • Jiangxi Haoran Bio-Pharma Co., Ltd.
  • Kraeber & Co GmbH
  • LIVZON Pharmaceutical Group Inc.
  • Midas Pharma GmbH
  • Microbix Biosystems Inc.
  • Microbic Biosystems Inc.
  • Mochida Pharmaceutical Co., Ltd.
  • NDPharm Co., Ltd.
  • Samarth Life Sciences Pvt. Ltd.

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP34469

Global Urokinase Market to Reach US$2.4 Billion by 2030

The global market for Urokinase estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Urokinase Powder, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Urokinase Solution segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$502.9 Million While China is Forecast to Grow at 8.5% CAGR

The Urokinase market in the U.S. is estimated at US$502.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$506.0 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Urokinase Market - Key Trends & Drivers Summarized

Why Is Urokinase Gaining Renewed Clinical Attention in Thrombolytic Therapies?

Urokinase is reemerging as a critical agent in the global thrombolytic therapy landscape, especially in the management of pulmonary embolism, deep vein thrombosis (DVT), and catheter occlusions. As cardiovascular diseases and thrombotic disorders continue to dominate global morbidity and mortality statistics, the need for efficient clot-dissolving agents is paramount. Urokinase, a serine protease enzyme originally derived from human kidney cells, functions by converting plasminogen into plasmin, which breaks down fibrin clots. Unlike some of its synthetic counterparts, urokinase is notable for its low immunogenicity and direct plasminogen activation, making it highly effective in cases requiring rapid thrombolysis. Its application has also extended beyond vascular use into off-label areas like intrapleural fibrinolytic therapy for empyema and loculated pleural effusions. With increasing clinical evidence supporting its efficacy in restoring catheter patency in hemodialysis and central venous access, urokinase is gaining traction among healthcare providers seeking alternatives to alteplase and streptokinase. Amid growing concerns over cost and availability of newer biologics, urokinase’s comparatively stable production pipeline is positioning it as a go-to thrombolytic in critical care settings.

How Are Technological Advances Improving Urokinase Manufacturing and Stability?

Modern biotechnological innovations are significantly advancing the production, purification, and stability of urokinase. Traditionally sourced from human urine or renal cell cultures, recent shifts have focused on recombinant DNA technologies and cell culture optimization to enhance yield, purity, and scalability. Manufacturers are increasingly adopting Chinese Hamster Ovary (CHO) cell lines and other expression systems to produce urokinase with higher consistency and reduced biological contaminants. Freeze-dried (lyophilized) formulations have improved the shelf-life and storage requirements of urokinase, enabling broader use in emergency and rural care settings. Additionally, progress in enzyme stabilization technologies has resulted in temperature-resistant formulations that are easier to transport and administer without cold-chain dependency. Analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry are now routinely employed to ensure potency and batch uniformity, which is critical in highly regulated pharmaceutical markets. These enhancements are not only reducing production costs but also facilitating regulatory compliance, paving the way for wider availability across both developed and emerging healthcare systems.

What Clinical and Market Trends Are Broadening Urokinase’s Applications?

Urokinase’s application base is expanding, driven by shifting clinical protocols and growing global healthcare access. Hospitals and outpatient centers are increasingly utilizing urokinase to restore function in occluded catheters used in chemotherapy, parenteral nutrition, and dialysis, where catheter blockage can otherwise lead to expensive replacements or serious infections. In critical care, urokinase is used in selective thrombolysis protocols where systemic administration of stronger agents may pose excessive bleeding risk. The drug is also becoming more prominent in pediatric thrombolysis due to its comparatively favorable safety profile. Geographic disparities in the availability and cost of thrombolytic agents are also shaping urokinase's market trajectory; in many lower- and middle-income countries, urokinase remains the primary clot-dissolving option due to affordability and simpler production logistics. Regulatory bodies in Asia and Latin America have been particularly supportive, accelerating approval pathways and incorporating urokinase into national treatment guidelines. Additionally, as antibiotic resistance rises and complications from indwelling catheters increase, urokinase’s role in infection-prevention and clot-dissolution at early stages is gaining prominence among clinicians.

What Are the Key Drivers Behind the Expansion of the Global Urokinase Market?

The growth in the urokinase market is driven by several factors anchored in clinical demand, biomanufacturing developments, and evolving treatment protocols. A significant driver is the rising incidence of thromboembolic events, particularly among aging populations and patients with comorbidities such as cancer and chronic kidney disease. This is increasing the demand for reliable thrombolytic agents with proven safety profiles in fragile patient groups. Advances in recombinant production technologies are enabling more cost-efficient and scalable manufacturing, expanding access in both high-income and resource-constrained settings. The growing use of central venous catheters and dialysis lines is also boosting demand for urokinase as a catheter patency agent. In parallel, institutional cost-containment strategies and payer pressure are prompting healthcare providers to seek alternatives to expensive newer biologics, making urokinase a favored choice in formulary planning. Regulatory support in Asia-Pacific and Latin American markets, combined with renewed inclusion in clinical guidelines for specific use cases, is further enhancing market penetration. Lastly, the push toward decentralizing thrombolytic care into ambulatory and outpatient settings is opening new channels for urokinase adoption beyond traditional hospital environments.

SCOPE OF STUDY:

The report analyzes the Urokinase market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Urokinase Powder, Urokinase Solution); End-Use (Hospitals, Clinics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abbott Laboratories
  • Agrata Biotech Ltd.
  • BBT Biotech GmbH
  • Bharat Serums and Vaccines Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Cerbios-Pharma SA
  • Echelon Biosciences Inc.
  • Hanways Chempharm Co., Ltd.
  • Health Biotech Ltd.
  • ImaRx Therapeutics, Inc.
  • Jiangsu Aidea Pharmaceutical Co., Ltd.
  • Jiangxi Haoran Bio-Pharma Co., Ltd.
  • Kraeber & Co GmbH
  • LIVZON Pharmaceutical Group Inc.
  • Midas Pharma GmbH
  • Microbix Biosystems Inc.
  • Microbic Biosystems Inc.
  • Mochida Pharmaceutical Co., Ltd.
  • NDPharm Co., Ltd.
  • Samarth Life Sciences Pvt. Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Urokinase - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Deep Vein Thrombosis and Pulmonary Embolism Drives Demand
    • Technological Innovation in Thrombolytic Therapies Strengthens Clinical Adoption
    • Rising Preference for Enzymatic Clot Dissolution Spurs Growth in Critical Care Settings
    • Expanding Use in Catheter Clearance Procedures Generates Steady Demand
    • Cost-Effectiveness Over Surgical Alternatives Propels Use in Resource-Limited Settings
    • Supportive Clinical Guidelines and Reimbursement Policies Expand Addressable Market
    • Partnerships Between Pharma Firms and Hospitals Drive Wider Product Penetration
    • Favorable Regulatory Landscape for Biologics Spurs Innovation and Launches
    • Surge in Cardiovascular Disorders Throw the Spotlight on Urokinase-Based Therapies
    • Increase in ICU Admissions for COVID-Related Thrombosis Accelerates Market Adoption
    • Biotech Investments in Recombinant Enzyme Production Sustain Supply Chain Expansion
    • Hospital and Emergency Room Protocols Standardize Urokinase Use in Acute Scenarios
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Urokinase Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Urokinase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Urokinase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Urokinase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Urokinase Powder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Urokinase Powder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Urokinase Powder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Urokinase Solution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Urokinase Solution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Urokinase Solution by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Urokinase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: USA 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: Canada 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • JAPAN
    • Urokinase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Japan 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • CHINA
    • Urokinase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: China 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • EUROPE
    • Urokinase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Urokinase by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Urokinase by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Europe 15-Year Perspective for Urokinase by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • FRANCE
    • Urokinase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: France 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • GERMANY
    • Urokinase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Germany 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Italy 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Urokinase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: UK 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Spain 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Russia 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Urokinase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Urokinase by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Urokinase by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for Urokinase by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Urokinase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Australia 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • INDIA
    • Urokinase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: India 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: South Korea 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Urokinase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Urokinase by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Urokinase by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Latin America 15-Year Perspective for Urokinase by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Argentina 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Brazil 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Mexico 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Urokinase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Urokinase by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Urokinase by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Middle East 15-Year Perspective for Urokinase by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Iran 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Israel 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: UAE 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • AFRICA
    • Urokinase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Urokinase by Type - Urokinase Powder and Urokinase Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Urokinase by Type - Urokinase Powder and Urokinase Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Africa 15-Year Perspective for Urokinase by Type - Percentage Breakdown of Value Sales for Urokinase Powder and Urokinase Solution for the Years 2015, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Urokinase by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Urokinase by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Urokinase by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030

IV. COMPETITION